Navigation Links
Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
Date:10/22/2007

n patients with advanced solid tumors and in patients co-infected with HCV and HIV.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the protocol will not be approved, the risk that the company will experience delays or difficulties in enrolling patients in the study, and the risk that the results from this trial will not be consistent with the results of prior trials or pre-clinical studies. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2007 and quarterly report on Form 10-Q for the quarter ended July 31, 2007. The company cautions investors not to place undue re
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
2. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
3. Peregrine Pharmaceuticals Highlights Significant Advances in the Companys Clinical and Preclinical Cancer Programs Presented This Week at the AACR Annual Meeting
4. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
5. Data Presented at AACR Meeting Show Peregrines Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer
6. Data Presented at AACR Meeting Shows Peregrines Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models
7. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  In today,s marketplace, ... costly and challenging - as is managing a portfolio ... Is it possible - or even preferable - ... so, where can you combine resources and activities, and ... These are just a few of the ...
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- ScriptPro, of ... of Powers Lake, Wisconsin , ... a distribution and co-marketing agreement allowing ScriptPro to ... throughout the United States . ... management and workflow systems to retail and ambulatory ...
(Date:7/25/2014)... , July 25, 2014  The Chemistry, Food ... Ministry of Health approved the introduction of Telaprevir ... the cure rate from Hepatitis C, and it ... 1 virus. Telaprevir is available in ... Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg   ...
Breaking Medicine Technology:Using Promotional Efficiency to Support Multiple Products and Indications in the Pharmaceutical Marketplace 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 2ScriptPro and TCGRx Integrate Pharmacy Automation Technologies 3The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3
... Filtrona Porous Technologies, a custom developer and manufacturer ... to absorb, retain, transfer, filter or release fluids ... polyurethane foams and bonded fibers at the MEDICA ... 17 to 19 November 2010. ...
... Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics ... Moch, President and Chief Executive Officer, will present at ... Wednesday, November 17, 2010, 10:30 a.m. ET, at the ... Mr. Moch will give an update on the company,s ...
Cached Medicine Technology:Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference 2
(Date:7/28/2014)... According to the Greek God Muscle Building Program review ... that teaches men how to completely transform their physique by ... its review that inside the Greek God Muscle Building Program ... gain the maximum muscle fiber recovery , ... gain , Ways to incorporate the specialization routines ...
(Date:7/28/2014)... 28, 2014 To commemorate World Hepatitis ... of Living with a Disability magazine has ... disorders that include hepatitis, gastrointestinal hemorrhage, inflammatory bowel disease, ... important new article highlights that, in the context of ... hepatitis and other disabling conditions related to the digestive ...
(Date:7/28/2014)... 28, 2014 Greta Pontarelli, 63, won her ... Champion title at the World Pole Sports Championships in London ... this athlete. She is the only U.S. competitor to qualify, ... Pole Sports Federation (IPSF). Over 150 athletes ranging in age ... in the competition. Pontarelli scored first place in the Masters ...
(Date:7/27/2014)... 28, 2014 Zensah®, the leader in compression ... include a wrist support . The wrist support features ... area. , Lateral and Medial Epicondylitis, more commonly referred to ... which there is inflammation of the tendons attached to the ... wrist pain, the muscles that work the wrist and fingers ...
(Date:7/27/2014)... regimens could provide shorter, more effective treatment options with ... with hepatitis C, even those most difficult to treat, ... The Lancet . , Both studies focused on ... genotype in the USA, Europe, North Asia, Australia, and ... treat. , Around 150 million people worldwide have chronic ...
Breaking Medicine News(10 mins):Health News:Greek God Muscle Building Program Review Exposes Greg O’Gallagher's Muscle Building Guide for Men – Vkool.com 2Health News:Greek God Muscle Building Program Review Exposes Greg O’Gallagher's Muscle Building Guide for Men – Vkool.com 3Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 2Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 3Health News:Inspiring Senior Athlete Lands Third World Title in One Year 2Health News:Zensah® Releases New Wrist Support 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 2Health News:The Lancet: New oral drug regimens cure hardest-to-treat hepatitis C 3
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today announced it ... 5, 2009. In conjunction, the Company will host a conference call at ... update. , , Date: ... Conference call access:, Internet: www.istavision.com, ...
... KALAMAZOO, Mich., July 29 Stryker Corporation (NYSE: ... Directors to nine and the election of Dr. Srikant M. Datar as ... Associate Dean and Director of Research at the Graduate School of Business ... at Harvard University since joining that organization in 1996. , , ...
... , , , , ... a worldwide leader in the development, distribution and use of ... $5 million financing commitment from Toronto-based MMV Financial ("MMV"). ... on-going cutting-edge clinical research, including immunotherapy and focal therapy, for ...
... ... of being overbilled, double-billed or billed for expenses they didn,t incur. , ... Norwalk, CT (PRWEB) July 29, 2009 -- ccording ... role in fully half of all U.S. foreclosures. CreditFYI, an educational consumer website on ...
... , , NEW YORK, July ... Cristie Kerr in 2003 with a mission to raise funds and ... classic will be held at Liberty National. The event, on Friday, ... a dinner reception and poker tournament. Renowned celebrity chef Todd ...
... North Carolina are reporting assembly of the first functioning ... inside cells helps process and package hormones, enzymes, and ... The lab-on-a-chip device could lead to a faster and ... or blood thinner, the researchers note. Their study is ...
Cached Medicine News:Health News:Stryker Announces Election of New Director 2Health News:US HIFU Secures $5 Million Financing From MMV Financial 2Health News:US HIFU Secures $5 Million Financing From MMV Financial 3Health News:As Medical Bills Contribute to 50% of U.S. Foreclosures, CreditFYI Shares 5 Tactics for Managing Medical Debt 2Health News:Birdies for Breast Cancer Announces Fifth Annual Charity Golf Classic Hosted by Top Women's Golfer, Cristie Kerr 2
Flattened points in vertical plane, straight shafts, cross action, round handle....
Karate chopper, spear shaped for ease of insertion into the nucleus....
Round serrated handle, dull finish....
Specially designed wider jaws to help split soft nucleus, cross action, round handle, maximum opening 2.8 mm....
Medicine Products: